OMER Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Omeros's net margin of -49.65%. Omeros's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 1065.05%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 54.55%. Given that Omeros has higher upside potential than NovaBay Pharmaceuticals, analysts believe Omeros is more attractive than NovaBay Pharmaceuticals.

Omeros has a beta of 2.421, which suggesting that the stock is 142.108% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Omeros's net income of -$33.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Omeros's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Omeros's net margin of --. Omeros's return on equity of -- beat Oragenics's return on equity of --.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 1065.05%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 733.33%. Given that Omeros has higher upside potential than Oragenics, analysts believe Omeros is more attractive than Oragenics.

Omeros has a beta of 2.421, which suggesting that the stock is 142.108% more volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Omeros's net income of -$33.5M is lower than Oragenics's net income of -$2.2M. Notably, Omeros's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus 1.15x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Omeros's net margin of --. Omeros's return on equity of -- beat Theriva Biologics's return on equity of --.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 1065.05%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1399.25%. Given that Theriva Biologics has higher upside potential than Omeros, analysts believe Theriva Biologics is more attractive than Omeros.

Omeros has a beta of 2.421, which suggesting that the stock is 142.108% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Omeros's net income of -$33.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Omeros's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

ZyVersa Therapeutics has a net margin of -- compared to Omeros's net margin of --. Omeros's return on equity of -- beat ZyVersa Therapeutics's return on equity of --.

Omeros has a consensus price target of $36.00, signalling upside risk potential of 1065.05%. On the other hand ZyVersa Therapeutics has an analysts' consensus of $70.00 which suggests that it could grow by 3080.66%. Given that ZyVersa Therapeutics has higher upside potential than Omeros, analysts believe ZyVersa Therapeutics is more attractive than Omeros.

Omeros has a beta of 2.421, which suggesting that the stock is 142.108% more volatile than S&P 500. In comparison ZyVersa Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Omeros has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ZyVersa Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros pays -- of its earnings as a dividend. ZyVersa Therapeutics pays out -- of its earnings as a dividend.

Omeros quarterly revenues are --, which are smaller than ZyVersa Therapeutics quarterly revenues of --. Omeros's net income of -$33.5M is lower than ZyVersa Therapeutics's net income of -$2.3M. Notably, Omeros's price-to-earnings ratio is -- while ZyVersa Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros is -- versus -- for ZyVersa Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.